Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients

Characteristics of Immune-Related Thyroid Adverse Events in Patients Treated with PD-1/PD-L1 Inhibitors

(2021) Jee Hee Yoon et al.   Endocrinology and Metabolism

Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study

(2020) Norio Okada et al.   BRITISH JOURNAL OF CANCER

Immune Checkpoint Inhibitor-Induced Thyroiditis Is Associated with Increased Intrathyroidal T Lymphocyte Subpopulations

(2020) Anupam Kotwal et al.   THYROID

Clinical Challenges of Immune Checkpoint Inhibitors

(2020) Maria de Miguel et al.   CANCER CELL

Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors

(2020) Joana Lima Ferreira et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Immune Checkpoint Inhibitor-Induced Thyroid Dysfunction is Associated with Higher Body Mass Index

(2020) Rena Pollack et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Higher thyroid hormone levels and cancer

(2020) Petra Petranović Ovčariček et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable

(2019) Alessio Cortellini et al.   Journal for ImmunoTherapy of Cancer

Targeting immune cells for cancer therapy

(2019) Sin Yee Gun et al.   Redox Biology

Incidence of thyroid dysfunctions during treatment with nivolumab for non-small cell lung cancer: Retrospective study of 105 patients

(2019) Pauline Campredon et al.   PRESSE MEDICALE

Low frequency of positive antithyroid antibodies is observed in patients with thyroid dysfunction related to immune check point inhibitors

(2019) I. Mazarico et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors

(2019) Satya Das et al.   Journal for ImmunoTherapy of Cancer

PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients

(2019) Anupam Kotwal et al.   THYROID

Association Between Body Mass Index and Overall Survival With Immune Checkpoint Inhibitor Therapy for Advanced Non–Small Cell Lung Cancer

(2019) Ganessan Kichenadasse et al.   JAMA Oncology

Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis

(2018) Jennifer L McQuade et al.   LANCET ONCOLOGY

Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens

(2018) Romualdo Barroso-Sousa et al.   JAMA Oncology

Endocrine toxicity of cancer immunotherapy targeting immune checkpoints

(2018) Lee-Shing Chang et al.   ENDOCRINE REVIEWS

Immune-Related Thyroiditis with Immune Checkpoint Inhibitors

(2018) Priyanka C. Iyer et al.   THYROID

Histology of Nivolumab-Induced Thyroiditis

(2018) Christina Neppl et al.   THYROID

Pembrolizumab-Induced Thyroiditis: Comprehensive Clinical Review and Insights Into Underlying Involved Mechanisms

(2017) Danae A Delivanis et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study

(2017) Ichiro Yamauchi et al.   THYROID

Antibody-Mediated Thyroid Dysfunction During T-cell Checkpoint Blockade in Patients with Non-Small Cell Lung Cancer

(2016) J.C. Osorio et al.   ANNALS OF ONCOLOGY

Endocrinological side-effects of immune checkpoint inhibitors

(2016) Francesco Torino et al.   CURRENT OPINION IN ONCOLOGY

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab

(2016) Jeroen de Filette et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study

(2016) David F. McDermott et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events

(2016) Elisa González-Rodríguez et al.   ONCOLOGIST

Treatment of the Immune-Related Adverse Effects of Immune Checkpoint Inhibitors

(2016) Claire F. Friedman et al.   JAMA Oncology

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic Potential and Challenges of Natural Killer Cells in Treatment of Solid Tumors

(2015) Andrea Gras Navarro et al.   Frontiers in Immunology

Shaping the repertoire of tumor-infiltrating effector and regulatory T cells

(2014) Peter A. Savage et al.   IMMUNOLOGICAL REVIEWS

Th17 Cells in Cancer: The Ultimate Identity Crisis

(2014) Stefanie R. Bailey et al.   Frontiers in Immunology

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression

(2014) Damya Laoui et al.   Frontiers in Immunology

PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

(2009) Loise M. Francisco et al.   JOURNAL OF EXPERIMENTAL MEDICINE